At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jia Ruan (Weill Cornell Medical College, New York, NY) discusses a phase II study of the biologic doublet of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma, including the trial design, efficacy and safety endpoints, and results.
Part 1: http://www.oncologytube.com/v/1034706/dr-jia-ruan-at-ash-2014-phase-ii-study-of-lenalidomide-plus-rituximab-as-initial-treatment-for-mantle-cell-lymphoma
Part 2: http://www.oncologytube.com/v/1034707/dr-jia-ruan-at-ash-2014-phase-ii-study-of-lenalidomide-plus-rituximab-as-initial-treatment-for-mantle-cell-lymphoma
This programme has been supported by sponsorship from Celgene
European Medical Journal
Website: http://emjreviews.com/
Twitter: https://twitter.com/EMJReviews
Facebook: https://www.facebook.com/emjreviews